SCHEMBL508517

SCHEMBL508517

OC1=CC=CON1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888121 0.69
SCHEMBL7518548 0.67
SCHEMBL3259932 0.67
SCHEMBL9813262 0.67
SCHEMBL29098440 0.67
SCHEMBL8488894 0.67
SCHEMBL4853981 0.67
SCHEMBL10423895 0.67
SCHEMBL7974834 0.67
Hydrochloric Acid SCHEMBL28898913 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116367815-A Uv absorbing nanoparticles and microparticles for intradermal use 科罗拉多大学董事会法人团体 2023-06-30 CN claimed
CN-117177989-A Activity-inducible fusion proteins with heat shock protein 90 binding domain 西雅图儿童医院以西雅图儿童研究机构名义经营 2023-12-05 CN disclosed
CN-116367815-A Uv absorbing nanoparticles and microparticles for intradermal use 科罗拉多大学董事会法人团体 2023-06-30 CN disclosed
CN-115996636-A Methods and compositions for plywood products 阿尔萨达股份公司 2023-04-21 CN disclosed
CN-114414707-B Method and kit for detecting 19 drugs and metabolites thereof in blood by liquid chromatography tandem mass spectrometry 北京和合医学诊断技术股份有限公司 2022-07-22 CN disclosed
CN-107083027-B Oxazine resin composition, method for producing same, prepreg, laminate, and cured product 日铁化学材料株式会社 2020-07-28 CN disclosed
CN-111032630-A Compound, pharmaceutical composition, application and application thereof 北京韩美药品有限公司 2020-04-17 CN disclosed
CN-106588937-B Imidazopyrazines and its preparation method and application 东莞市真兴贝特医药技术有限公司 2018-09-21 CN disclosed
CN-104583195-B Nitrogenous heteroaromatic ring derivative as tyrosine kinase inhibitor 山东亨利医药科技有限责任公司 2018-08-17 CN disclosed
CN-106588937-A Imidazopyrazine compound, and preparation method and application thereof 东莞市真兴贝特医药技术有限公司 2017-04-26 CN disclosed
US-6932961-B1 Oxazinocarbazoles for the treatment of CNS diseases PHARMACIA & UPJOHN COMPANY (US) 2005-08-23 US disclosed
EP-1495031-A1 LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS Pharmacia & Upjohn Company LLC (US) 2005-01-12 EP disclosed
US-6821970-B2 USEFUL FOR TREATING DISEASES WHEREIN MODULATION OF 5-HT ACTIVITY IS DESIRED; NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-11-23 US disclosed
WO-2003089438-A1 LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2003-10-30 WO disclosed
EP-1200447-B1 OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES UPJOHN CO (US) 2003-10-01 EP disclosed
US-20020169317-A1 Oxazinocarbazoles for the treatment of CNS diseases TENBRINK RUTH ELIZABETH (US) 2002-11-14 US disclosed
US-6448397-B1 TREATING CENTRAL NERVOUS SYSTEM DISEASES WITH MODULATION OF 5-HT ACTIVITY; ADRENERGIC, DOPAMINERGIC, AND SEROTONERGIC NEUROTRANSMITTERS; PSYCHOSIS, PARAPHRENIA, DEPRESSION, MANIA, SCHIZOPHRENIA, ANXIETY, MIGRAINE HEADACHE, DRUG ADDICTION PHARMACIA & UPJOHN COMPANY 2002-09-10 US disclosed
EP-1200447-A1 OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES PHARMACIA &amp; UPJOHN COMPANY (US) 2002-05-02 EP disclosed
WO-2001009142-A1 OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES PHARMACIA & UPJOHN COMPANY (US) 2001-02-08 WO disclosed
US-5635608-A CONTAINS PHOTOREMOVABLE ALPHA-CARBOXY-SUBSTITUTED ORTHO-NITROBENZYL GROUP THAT CHANGES THE FLUORESCENCE AND BIOLOGICAL PROPERTIES OF THE COMPOUND MOLECULAR PROBES, INC. (US) 1997-06-03 US disclosed